Birth Control Pill vs Birth Control Patch Study (PvP)

This study has been completed.
University of Vermont Medical Center
Information provided by:
University of Vermont Identifier:
First received: November 6, 2007
Last updated: NA
Last verified: October 2007
History: No changes posted
This study was a randomized, investigator-blinded, cross-over, clinic trial using twenty-four healthy women aged 18-35. All women received two months of the birth control patch or birth control pill, two months without any drug, then two months of the alternative drug. The birth control patch contained 0.75 milligrams ethinyl estradiol and 6 milligrams norelgestromin. The birth control pill contained 35 micrograms ethinyl estradiol and 250 micrograms norgestimate. Blood samples were taken before and after each treatment and were analyzed for the following lab values: D-dimer, von Willebrand factor, factor VIII, total and free protein S, antithrombin, fibrinogen, C-reactive protein and normalized activated protein C sensitivity ratio (nAPCsr). Two thrombin generation-based assays were used: the α2macroglobulin-thrombin endpoint method (α2M-IIa) and calibrated automated thrombinography (CAT).

Condition Intervention
Venous Thrombosis
Drug: Ethinyl estradiol and norgestimate
Drug: Ethinyl estradiol and norelgestromin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: The Effects of Oral Contraceptive Pills vs Hormonal Patch on Coagulation Parameters

Resource links provided by NLM:

Further study details as provided by University of Vermont:

Primary Outcome Measures:
  • Change in coagulation parameters on transdermal versus oral contraceptive [ Time Frame: 2003--2005 ]

Secondary Outcome Measures:
  • Compare ethinyl estradiol levels for transdermal versus oral contraceptives [ Time Frame: September 2007 ]

Enrollment: 24
Study Start Date: April 2003
Study Completion Date: August 2005
Arms Assigned Interventions
Active Comparator: 1
Use of transdermal hormonal contraceptive
Drug: Ethinyl estradiol and norelgestromin
Transdermal hormonal contraceptive changed weekly
Other Name: Ortho Evra
Active Comparator: 2
Use of oral hormonal contraceptive
Drug: Ethinyl estradiol and norgestimate
Oral contraceptive
Other Name: Ortho Cyclen

  Show Detailed Description


Ages Eligible for Study:   18 Years to 25 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Women ages 18-35 years of age
  • Not on hormones for at least 2 months prior to enrollment
  • Must be more than 3 months post-partum, &
  • Generally healthy.

Exclusion Criteria:

  • Women with prior history of contraindications to taking birth control pills
  • History of Deep Vein Thrombosis or Pulmonary Embolism
  • Known history of coagulation disorders
  • Liver disease
  • Pregnant or actively attempting pregnancy
  • Currently breastfeeding
  • Uncontrolled hypertension
  • Migraines with ischemic changes, &
  • Weight more than 199 lbs.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00554632

Sponsors and Collaborators
University of Vermont
University of Vermont Medical Center
Principal Investigator: Julia V Johnson, MD Fletcher Allen Health Care & University of Vermont
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00554632     History of Changes
Other Study ID Numbers: 03-168 
Study First Received: November 6, 2007
Last Updated: November 6, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by University of Vermont:
Venous thrombosis
Coagulation parameter

Additional relevant MeSH terms:
Venous Thrombosis
Cardiovascular Diseases
Embolism and Thrombosis
Vascular Diseases
Contraceptive Agents
Contraceptives, Oral
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Ethinyl Estradiol
Polyestradiol phosphate
Contraceptive Agents, Female
Contraceptives, Oral, Combined
Contraceptives, Oral, Synthetic
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses processed this record on April 27, 2016